DBVT — DBV Technologies SA Share Price
Last trade - 00:00- $176.96m
- $151.45m
- $4.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.46 | ||
| Price to Tang. Book | 6.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 42.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -338.57% | ||
| Return on Equity | -136.09% | ||
| Operating Margin | -2806% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11.28 | 5.71 | 4.84 | 15.73 | 4.15 | 2 | 5.96 | -22.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Directors
- Michel De Rosen NEC (70)
- Daniel Tasse CEO (61)
- Sebastien Robitaille CFO (51)
- Pharis Mohideen OTH (56)
- Michele Robertson OTH
- Mailys Ferrere NED (58)
- Michael Goller NED (46)
- Julie O'Neill NED (55)
- Adora Ndu IND (39)
- Ravi Rao IND (53)
- Viviane Monges NID (57)
- Timothy Morris NID (59)
- Daniel Soland NID (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 2002
- Public Since
- March 29th, 2012
- No. of Employees
- 110
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 102,580,633
- Address
- Batiment IRO, 107 Av. de la Republique, CHATILLON, 92320
- Web
- https://www.dbv-technologies.com/
- Phone
- +33 155427878
- Contact
- Katie Matthews
- Auditors
- Deloitte & Associes
Upcoming Events for DBVT
Similar to DBVT
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
As of Today at 20:12 UTC, shares in DBV Technologies SA are trading at $8.53. This share price information is delayed by 15 minutes.
Shares in DBV Technologies SA last closed at $8.53 and the price had moved by +23.72% over the past 365 days. In terms of relative price strength the DBV Technologies SA share price has outperformed the S&P500 Index by +14.2% over the past year.
The overall consensus recommendation for DBV Technologies SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDBV Technologies SA does not currently pay a dividend.
DBV Technologies SA does not currently pay a dividend.
DBV Technologies SA does not currently pay a dividend.
To buy shares in DBV Technologies SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $8.53, shares in DBV Technologies SA had a market capitalisation of $176.96m.
Here are the trading details for DBV Technologies SA:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DBVT
Based on an overall assessment of its quality, value and momentum DBV Technologies SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in DBV Technologies SA is $22.45. That is 163.21% above the last closing price of $8.53.
Analysts covering DBV Technologies SA currently have a consensus Earnings Per Share (EPS) forecast of -$1.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DBV Technologies SA. Over the past six months, its share price has outperformed the S&P500 Index by +107.51%.
As of the last closing price of $8.53, shares in DBV Technologies SA were trading +95.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DBV Technologies SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
DBV Technologies SA's management team is headed by:
- Michel De Rosen - NEC
- Daniel Tasse - CEO
- Sebastien Robitaille - CFO
- Pharis Mohideen - OTH
- Michele Robertson - OTH
- Mailys Ferrere - NED
- Michael Goller - NED
- Julie O'Neill - NED
- Adora Ndu - IND
- Ravi Rao - IND
- Viviane Monges - NID
- Timothy Morris - NID
- Daniel Soland - NID